Sabrina Welsh

Bivalent RSVpreF Effectiveness Against Respiratory Syncytial Virus (RSV)-Related Respiratory Disease Hospitalization and Emergency Department Visits Across Three RSV Seasons

Respiratory syncytial virus (RSV) protein subunit vaccines reduce the risk of severe outcomes such as hospitalization and emergency department (ED) visits for at least two RSV seasons following vaccination. No data have been published on real-world RSV vaccine effectiveness (VE)...

The Impact of Respiratory Syncytial Virus Undertesting on Estimates of Disease Burden and Vaccine Effectiveness in a Large Integrated Healthcare System

Abstract Infrequent standard-of-care (SOC) testing for respiratory syncytial virus (RSV) in adults with acute respiratory illness (ARI) contributes to underestimated disease burden. We compared RSV prevalence and RSV vaccine effectiveness (VE) among 14,044 adults ≥60 years with A...

Bivalent RSV Prefusion F Vaccine to Prevent Hospitalizations in Adults

BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of severe respiratory disease in adults, with the highest burden among older adults and individuals with chronic health conditions. The bivalent RSV prefusion F (RSVpreF) vaccine has been shown to prevent RSV-ass...

Durability of RSV Prefusion F Vaccine Protection across Two RSV Seasons

BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of hospitalization and death among older adults. Although first-season vaccine effectiveness against RSV-related hospitalization has been demonstrated for the bivalent RSV prefusion F protein-based vaccine (RSVpr...